ABCG2 and acute myeloid leukemia: In 2001, Sargent et al., evaluated ABCG2 expression by immunocytochemistry, using the anti ABCG2 BXP-34 monoclonal antibody, in 20 samples of de novo AML (12 previously treated and 8 untreated).